Table of Contents
Beta Blockers (Migraine) - Forecast and Market Analysis to 2023
The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
Among the various prophylaxis therapy classes for migraine, beta blockers are highly effective and are the most widely used class of drugs for the prophylaxis of migraine. Beta blockers were primarily developed for controlling cardiac symptoms but were coincidentally found to have an effect on migraine prevention. They have been used as migraine treatment since the 1970s. Their mechanism of action for preventing migraine is not clear, but beta receptors have been shown to be present in the pial vessel of the brain. The possible mechanisms of action of beta blockers include reducing the neuronal firing rate of noradrenergic neurons in the locus coeruleus, regulation of PAG neurons firing rate and possible inhibition of 5-HT2C and 5-HT2B receptor subtypes.
- Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Beta blockers including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Beta blockers for the top seven countries from 2012 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Migraine
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Beta blockers performance
- Obtain sales forecast for Beta blockers from 2012-2023 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
The global anxiety disorders and depression treatment market is expected to reach a value of USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated to drive the market growth ...
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline Summary Hypertension is a serious and common medical condition ...
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...